-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on BioLife Solutions (BLFS)
-
-
-
-
-
-
-
KeyBanc: 'Cell & Gene Therapy Getting More Support; BLFS, CYRX, TKNO With the Most Exposure'
-
-
-
-
-
-
-
BioLife Solutions (BLFS) PT Raised to $30 at H.C. Wainwright
-
-
-
-
-
-
-
BioLife Solutions (BLFS) PT Lowered to $27 at H.C. Wainwright
-
-
-
-
-
-
-
BioLife Solutions (BLFS) Misses Q2 EPS by 36c, provides guidance
416,699 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

